PRospective Observational Study of STereotactic Body rAdiation Therapy With Androgen Deprivation Therapy for Organ-confined High-risk Prostate Cancer: the PROSTAR Trial
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Istituto Clinico Humanitas
With
accord healthcare italia srl
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Age \> 18 years
ECOG performance status ≤ 2
Histologically proven prostate adenocarcinoma
High-risk group classification according to National Comprehensive Cancer Network (NCCN), defined by the presence of any one of the following high-risk factors: cT3-cT4 OR Grade Group 4 or Grade Group 5 OR PSA \>20 ng/mL
No pelvic nodal and distant metastases at staging with PSMA-PET
IPSS ≤ 15 (alpha blockers allowed)
Life expectancy of \> 5 years
Prostate volume ≤ 100 cc
You may not be if
Previous local radiation treatment of the prostate
Previous radiotherapy to the pelvis
Active Ulcerative Colitis or Crohn's Disease
Previous tumors unless disease free for a minimum of 5 years
Clareo Health | PRospective Observational Study of STereotactic Body rAdiation Therapy With Androgen Deprivation Therapy for Organ-confined High-risk Prostate Cancer: the PROSTAR Trial
